Emergent BioSolutions (EBS) Accumulated Expenses (2010 - 2026)

Emergent BioSolutions' Accumulated Expenses history runs 17 years deep, the most recent figure standing at $9.4 million for Q1 2026.

• In Q1 2026, Accumulated Expenses fell 28.79% year-over-year to $9.4 million; the TTM figure through Mar 2026 stood at $9.4 million (down 28.79% YoY), while the FY2025 annual figure was $12.2 million, down 78.25% from the prior year.
• Accumulated Expenses was $9.4 million for Q1 2026 at Emergent BioSolutions, down from $12.2 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $87.3 million in Q4 2022 to a low of $9.4 million in Q1 2026.
• Historically, Accumulated Expenses has averaged $34.3 million across 5 years, with a median of $31.2 million in 2023.
• Biggest YoY gain for Accumulated Expenses was 83.14% in 2025; the steepest drop was 78.25% in 2025.
• A 5-year view of Accumulated Expenses shows it stood at $87.3 million in 2022, then declined by 15.12% to $74.1 million in 2023, then decreased by 24.29% to $56.1 million in 2024, then plunged by 78.25% to $12.2 million in 2025, then fell by 22.95% to $9.4 million in 2026.
• The last three Accumulated Expenses figures came in at $9.4 million (Q1 2026), $12.2 million (Q4 2025), and $13.9 million (Q3 2025), per Business Quant data.